… , 2 More recently, it has been shown that erlotinib prolongs survival in previously treated
patients with NSCLC.2 Many patients who are treated with these agents, however, fail to benefit …

… 10 to 20 percent of patients who were previously treated with platinum-based regimens
responded, and in a phase 2 trial of erlotinib among previously treated patients with non–small-…

… survival benefit of monotherapy with erlotinib in patients with previously treated NSCLC. Our
study confirmed the benefit of erlotinib in previously treated patients with advanced NSCLC. …

… In previously treated EGFT-TKI-naive NSCLC patients, those … and OS than those receiving
erlotinib. Additional large-scale … erlotinib and gefitinib in previously treated NSCLC patients. …

… everolimus–erlotinib was efficacious and worthy of further study was not met. In the pivotal
phase III trial of erlotinib for previously treated NSCLC, DCR for erlotinib monotherapy was …

… was efficacious and was well tolerated in patients with previously treated NSCLC.13-15
However, the Iressa Survival Evaluation in Lung Cancer trial comparing gefitinib with placebo in …

… the usefulness of erlotinib in Japanese patients with previously treated EGFR-mt non-small-cell
lung cancer. Although this trial could not meet the primary endpoint, erlotinib was well …

… , 10% to 20% of patients previously treated with platinum-based regimens responded to
therapy. In a phase 2 trial of erlotinib among previously treated patients with NSCLC in which 10…

… Advanced NSCLC White patients, previously treated with almost two lines of chemotherapy
… agent, were treated with erlotinib after progression of disease to gefitinib. Only eight patients …

… The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated …
Erlotinib had limited activity in patients with esophageal cancer, and responses and some …